Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia

This study analysed the utilization of ibrutinib, a BTK inhibitor, in treating chronic lymphocytic leukemia in Australia. It compared real-world data from the Pharmaceutical Benefits Scheme (PBS) to the RESONATE clinical trial, providing insights into ibrutinib use in the general community compared to the selected trial population.

Authors: Stephen P Mulligan, Stephen Opat, Paula Marlton, Bryone Kuss, Poppy Gerungan, Andrea Puig, Marija McGeachie, Constantine S Tam

British Journal of Haematology https://onlinelibrary.wiley.com/doi/10.1111/bjh.18306 | Date: June 14, 2022

Download document